Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
about
X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with AtazanavirStructural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysisThe Geogenomic Mutational Atlas of Pathogens (GoMAP) web systemMachine learning on normalized protein sequences.Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesA multifaceted analysis of HIV-1 protease multidrug resistance phenotypesHIV-1 antiretroviral resistance: scientific principles and clinical applicationsMolecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Molecular Basis for Drug Resistance in HIV-1 ProteaseInterplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivityAtazanavir: new option for treatment of HIV infection.Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.Atazanavir for the treatment of human immunodeficiency virus infection.Atazanavir: the advent of a new generation of more convenient protease inhibitors.Review of atazanavir: a novel HIV protease inhibitor.Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems.Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialAtazanavir: simplicity and convenience in different scenarios.Clinical implications of HIV-1 minority variantsAnalysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavirHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTClinical significance of human immunodeficiency virus type 1 replication fitness.Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsLow frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort studyTreatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.Role of atazanavir in the treatment of HIV infectionAtazanavir: its role in HIV treatmentHuman immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Atazanavir: in pediatric patients with HIV-1 infection.Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.Identification of drug resistance mutations in HIV from constraints on natural evolution.Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
P2860
Q27645052-A1E21B02-8C61-4F09-B682-4976380CB96FQ27676079-89861976-EEDC-44B2-B91F-028F12A3477FQ28539260-6E4F737C-8AB2-44B0-BC13-687319D45771Q28541636-D2BAA019-0AFA-4DAF-B079-EB4A7F5427CBQ33858855-1114E6B7-D2FC-4462-B3D9-E73E0EAA4393Q33935276-1EACF3DC-1F2C-42C0-A118-A7DB90B57209Q34102058-9562249D-3D99-4A36-A01B-7298421AA1B6Q34280466-B3D6C1B7-A6BA-429B-96ED-C3BB1C2576ECQ34446445-7395C1D8-21C2-42AB-912D-95147A7E1ECFQ34529347-92A53772-1F9D-4E46-8A6E-FB4ECD6F9828Q34757951-93BC553C-0B06-4CB5-8C5C-8C5485B30FA7Q35079510-9A860AB5-B73D-4D70-939E-378F32F61AF3Q35260370-D6E42057-49AE-44F6-B39C-D1FC35AE9E0CQ35689381-D063C2D4-2A42-4732-B648-84323575BC6AQ35779915-E8AF3346-8ECD-46CC-846E-0FCB778EFE54Q35783809-60D5A5F3-7DF3-4CDD-9015-A11EDA6E18CBQ35976835-58216029-285F-466D-8515-2FAB0F235A8CQ36070100-73797D32-886B-4473-A041-B49CCA7927F5Q36222006-16EFF895-3FC1-4380-A4F0-C054F314287DQ36538695-0BCC6251-42DA-43C1-A440-972CF60B848BQ36543455-8C7AC044-4E9F-4004-BE16-B09496C9A3E6Q36627942-1FEA7E21-0BF1-4BD4-B27D-5FEE27251763Q36765802-9DEE3521-84C4-4934-9467-8D228707E7C4Q36811249-75B1FCA0-061C-415C-964C-E4E2F67E681DQ36841895-48DE43AC-4EB4-426C-A929-C7A6EB80C2F0Q36900010-DC68598E-AE1B-407C-8EEE-DD4427E90699Q36969857-DBF4E82E-D6D3-4DED-A0F3-FCD107FF13F0Q37127869-30356B62-151B-40BC-B75B-BE1282FD331BQ37169938-CDF8ECB8-43A8-46B5-9DAC-36C2BF8EB661Q37200979-96F5175F-DE9A-4B50-97B3-678597A2702BQ37230298-4768A00F-25E4-4854-93A4-56CD0B7D6A98Q37249418-22D35AD0-F33E-47FA-A273-EA1E8588B13BQ37410823-59D6E1E4-9B09-4927-BF10-341F932D9B25Q37980179-CA1F1C4C-5F8B-4A30-BFB8-3B2709C2A66AQ38162985-C6A24E8B-D28C-49E0-B2E4-722AA5903BCAQ38726300-3D0BE53C-ACE5-4871-BE8B-B5940897E462Q38865547-05972070-687D-4322-BAC5-38D256823E51Q38935015-0A5775A7-9186-4854-85CE-D24E923D7B41Q39913095-A20F3AD7-2633-458B-8328-51BE5C070402Q42120771-8D2CC1AD-659F-4F67-BE94-A604DBC09C93
P2860
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Identification of I50L as the ...... iving ATV-containing regimens.
@en
Identification of I50L as the signature atazanavir
@nl
type
label
Identification of I50L as the ...... iving ATV-containing regimens.
@en
Identification of I50L as the signature atazanavir
@nl
prefLabel
Identification of I50L as the ...... iving ATV-containing regimens.
@en
Identification of I50L as the signature atazanavir
@nl
P2093
P356
P1476
Identification of I50L as the ...... iving ATV-containing regimens.
@en
P2093
Alexandra Thiry
Colin McLaren
Jacques Friborg
Neil Parkin
Richard Colonno
Ronald Rose
P304
P356
10.1086/386291
P407
P577
2004-04-27T00:00:00Z